How To Accelerate and De-Risk Drug Development in Oncology
Despite more than a century of dedicated research, cancer remains one of the leading causes of death. Recent years have seen significant advances in treatment, however, there is still much to be done to ensure that scientific developments result in clinically meaningful improvements. On average, only 3% of oncology drugs ever make it to market, and many of those that do make a limited difference to quantity or quality of life for patients.
Although there are initiatives to de-risk the drug development process, continually applying the same tools and approaches is unlikely to lead to innovative, first- or best-in-class targets and transformative progress.
Download this white paper to learn about the key reasons why oncology drug development fails and how Biognosys’ proteomics platforms and applications can support oncology research by:
- Understanding the right biology
- Hitting the right target
- Developing the right biomarkers